Catalent (CTLT)
(Delayed Data from NYSE)
$58.40 USD
-0.02 (-0.03%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $58.42 +0.02 (0.03%) 7:58 PM ET
5-Strong Sell of 5 5
D Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Catalent, Inc. [CTLT]
Reports for Purchase
Showing records 41 - 60 ( 217 total )
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
GLP-1 Market Opportunity Update, 2028 Consensus Estimates +11% vs. April Report
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
3Q23 - Guidance Granularity, FY24 Needs Sarepta Tailwind
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Poor Execution Behind Preannouncement & CFO Departure
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Obesity/Diabetes Therapeutics, Far Surpassing Estimates
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Model Update with Better Clarity Around Sarepta and COVID
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
2Q23 - Improved Results and Upbeat Cell & Gene Therapy Outlook
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Positive Announcements Rolling Out at JPM
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Life Science Technology - Biologic Transformation Continues - 2023 Outlook
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department